Focus on deacetylation for therapeutic benefit

IDrugs

Volumn 8, Issue 2, 2005, Pages 144-154

  Shabbeer, Shabana ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer clinical trials; Histone deacetylase; Histone deacetylase inhibitor; Mechanism; Preclinical; Re expression

Indexed keywords

3 CARBOXYCINNAMIC ACID BISHYDROXAMIDE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CISPLATIN; DNA METHYLTRANSFERASE; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; FR 901228; GYRASE INHIBITOR; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LBH 589A; METHYLTRANSFERASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHENYLACETIC ACID; PIVALOYLOXYMETHYL BUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANEMIA; ANOREXIA; APOPTOSIS; APPETITE DISORDER; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEACETYLATION; DIARRHEA; DISORIENTATION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DYSGEUSIA; DYSPEPSIA; EDEMA; EPIGENETICS; EXPERIMENTAL NEOPLASM; FATIGUE; GENE EXPRESSION; GENE SILENCING; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LETHARGY; MALAISE; METABOLIC DISORDER; MITOSIS INHIBITION; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PLEIOTROPY; REVIEW; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING;

ACETYLATION; ANIMALS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 14544277978     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature (1997) 389(6648):251-260.
2. Waterborg JH: Dynamics of histone acetylation in vivo A function for acetylation turnover? Biochem Cell Biol (2002) 80(3):363-378.
3. Fischle W, Wang Y, Allis CD: Binary switches and modification cassettes in histone biology and beyond. Nature (2003) 425(6957):475-479.
4. Gray SG, Ekstrom TJ: The human histone deacetylase family. Exp Cell Res (2001) 262(2):75-83.
5. Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem (2001) 70:81-120.
6. Grozinger CM, Hassig CA, Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA (1999) 96(9):4868-4873.
7. Verdin E, Dequiedt F, Kasler HG: Class II histone deacetylases: Versatile regulators. Trends Genet (2003) 19 5):286-293.
8. Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol (2004) 338(1):17-31.
9. Robyr D, Suka Y, Xenarios I, Kurdistani SK, Wang A, Suka N, Grunstein M: Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell (2002) 109 4):437-446.
10. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol (2004) 24(19):8467-8476.
11. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 5(5):455-463.
12. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res (2001) 92(12):1300-1304.
13. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D: Functional significance of histone deacetylase diversity. Curr Opin Genet Dev (2001) 11(2):162-166.
14. Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A: The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem (2003) 278(18):16059-16072.
15. McGraw S, Robert C, Massicotte L, Sirard MA: Quantification of histone acetyltransferase and histone deacetylase transcripts during early bovine embryo development. Biol Reprod (2003) 68(2):383-389.
16. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J (2002) 21 11):2672-2681.
17. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM: Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med (2002) 166 3):392-396.
18. McKinsey TA, Olson EN: Dual roles of histone deacetylases in the control of cardiac growth. Novartis Foundation Symposium (2004) 259:132-141.
19. Di Croce L, Raker VA, Corsaro M, Fezi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 296(5557):1079-1082.
20. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C et al: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA (2004) 101 42):15064-15069.
21. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2005) 11(1):71-76.
22. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 349(21):2042-2054.
23. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 3(6):415-428.
24. El-Osta A, Kanthaddis P, Zalcberg JR, Wolffe AP: Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol (2002) 22(6):1844-1857.
25. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA (1996) 93(12):5705-5708.
26. Candido EP, Reeves R, Davie JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell (1978) 14 1):105-113.
27. Nudelman A, Gnizi E, Katz Y, Azulai R, Cohen-Ohana M, Zhuk R, Sampson SR, Langzam L, Fibach E, Prus E, Pugach V et al: Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem (2001) 36(1):63-74.
28. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401(6749):188-193.
29. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem (2004) 47 2):467-474.
30. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S: FK-228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res (2002) 62(17):4916-4921.
31. Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Bouska JJ, Murphy SS et al: Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett (2002) 12(23):3443-3447.
32. Vasudevan A, Ji Z, Frey RR, Wada CK, Steinman D, Heyman HR, Guo Y, Curtin ML, Guo J, Li J, Pease L et al: Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett (2003) 13(22):3909-3913.
33. Yoshida M, Kijima M, Akita M, Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by Trichostatin A. J Biol Chem (1990) 265 28):17174-17179.
34. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 7(4):971-976.
35. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res (2004) 10(3):1141-1149.
36. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H: Identification of genes upregulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol (2004) 41 3):436-445.
37. Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R, Marks PA, Richon VM, LaQuaglia MP: Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol (2000) 36(6):577-581.
38. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res (1996) 2(2):379-387.
39. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 60(18):5165-5170.
40. 2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell (2000) 11(6):2069-2083.
41. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA (2003) 100(8):4389-4394.
42. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA (2000) 97(18):10014-10019.
43. CIP1, but independent of p53. Oncogene (1999) 18 50):7016-7025.
44. 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR-901228. Br J Cancer (2000) 83 6):817-825.
45. Glaser KB, Slaver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 2 2):151-163.
46. WAF1/CIP1, by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol (2001) 60(4):828-837.
47. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, Gabrielli B: Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J (2003) 17(11):1550-1552.
48. Johnstone RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Disc (2002) 1 4):287-299.
49. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA (2004) 101(2):540-545.
50. Chen Z, Clark S, Birkeland M, Sung CM, Logo A, Liu R, Kirkpatrick R, Johanson K, Winkler JD, Hu E: Induction and superinduction of growth arrest and DNA damage gone 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett (2002) 188(1-2):127-140.
51. Henderson C, Brancolini C: Apoptotic pathways activated by histone deacetylase inhibitors: Implications for the drug-resistant phenotype. Drug Resistance Updates (2003) 6(5):247-256.
52. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem (2003) 278(14):12579-12589.
53. Zhang XD, Gillespie SK, Borrow JM, Hersey P: The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol (2003) 66(8):1537-1545.
54. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM et al: Depsipeptide (FR-901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood (2003) 102(2):652-658.
55. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, Porta CA: Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis (2004) 9(5):573-582.
56. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG: Antitumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer (1999) 80(8):1252-1258.
57. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene (2004) 23 40):6693-6701.
58. Rahman I, Marwick J, Kirkham P: Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NFκB and pro-inflammatory gene expression. Biochem Pharmacol (2004) 68(6):1255-1267.
59. CIP1/WAF1. Cancer Res (2003) 63(13):3637-3645.
60. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA (2001) 98(19):10833-10838.
61. WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol (2001) 19(1):181-191.
62. WAF1. Exp Cell Res (2004) 298(2):560-573.
63. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 20(24):6969-6978.
64. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA (1999) 96 8):4592-4597.
65. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res (2002) 22(3):1497-1504.
66. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 21 3):427-436.
67. Kwon HJ, Kim MS, Kim W, Nakajima H, Kim KW: Histone deacetylase inhibitor FK-228 inhibits tumor angiogenesis. Int J Cancer (2002) 97(3):290-296.
68. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pill R: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK-787/ZK-222584. Cancer Res (2004) 64(18):6626-6634.
69. Myzak MC, Karplus PA, Chung FL, Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res (2004) 64(16):5767-5774.
70. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD-101. Mol Cancer Ther (2003) 2 8):721-728.
71. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI et al: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res (2001) 7(4):962-970.
72. Beck J, Fischer T, Rowinsky E, Huber C, Mita M, Atadja P, Peng B, Kwong C, Dugan M, Patnaik A: Phase I pharmacokinetic and pharmacodynamic study of LBH-589A: A novel histone deacetylase inhibitor. Proc Am Soc Clin Oncol (2004) 23:Abs 3025.
73. Gore L, Holden SN, Basche M, Raj SKS, Arnold I, O'Bryant C, Witta S, Rohde B, McCoy C, Eckhardt SG: Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-276 in patients with refractory solid tumors. Proc Am Soc Clin Oncol (2004) 23 Abs 3026.
74. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC: A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res (2001) 7 10):3047-3055.
75. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 90(21):1621-1625.
76. Huang L, Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med (2000) 6(10):849-866.
77. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 61 4):1477-1485.
78. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res (2000) 60(24):6890-6894.
79. Rascle A, Johnston JA, Amati B: Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STATS. Mol Cell Biol (2003) 23 12):4162-4173.
80. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P et al: Histone deacetylase inhibitor LAQ-824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res (2003) 63(16):5126-5135.
81. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood (2003) 101 8):3236-3239.
82. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P et al: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA (2002) 99(5):2995-3000.
83. WAF1 regulation by laminar flow. J Biol Chem (2003) 278(27):24594-24599.
84. Vaghefi H, Nest KE: Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation. Oncogene (2004) 23(49):8078-8087.
85. Bereshchenko OR, Ou W, Dalla-Favera R: Acetylation inactivates the transcriptional repressor Bcl-6. Nat Genet (2002) 32(4):606-613.
86. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR-901228. J Natl Cancer Inst (2002) 94(7):504-513.
87. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM, Sinclair DA: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell (2004) 13(5):627-638.
88. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, Miller WH Jr: Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid-resistant APL cells. Blood (2002) 100(7):2586-2596.
89. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res (2001) 61(9):3591-3594.
90. Demary K, Wong L, Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett (2001) 163(1):103-107.
91. Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, Howard BH, Ozato K: A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci USA (1997) 94(21):11295-11300.
92. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 21(1):103-107.
93. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL: Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs (2002) 13 8):869-874.
94. Zhu WG, Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 3(3):187-199.
95. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat (2003) 81 3):177-186.
96. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 63 21):7089-7093.
97. Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL: Interaction of 5-aze-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3σ, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs (2003) 14(3):193-202.
98. Klisovic MI, Maghraby EA, Parthun MR, Gulmond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ et al: Depsipeptide (FR-901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia (2003) 17(2):350-358.
99. Primeau M, Gagnon J, Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer (2003) 103 2):177-184.
100. Bras-Goncalves RA, Pocard M, Formento JL, Poirson-Bichat F, De Pinieux G, Pandrea I, Arvelo F, Ronco G, Villa P, Coquette A, Milano G et al: Synergistic efficacy of 3N-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology (2001) 120(4):874-888.
101. WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol (2004) 65 3):571-581.
102. Almenara J, Rosato R, Grant S: Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia (2002) 16(7):1331-1343.
103. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS: Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res (2004) 10(5):1813-1825.
104. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovskii L, Dent P, Grant S: Histone deacetylase inhibitors promote STI-571-mediated apoptosis in STI-571-sensitive and - resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res (2003) 63 9):2118-2126.
105. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI-571. Blood (2003) 102(10):3765-3774.
106. Kim JS, Jeung HK, Cheong JW, Maeng H, Lee ST, Hahn JS, Ko YW, Min YH: Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br J Haematol (2004) 124(2):166-178.
107. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC, Kroll DJ: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II α expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther (2001) 1(2):121-131.
108. Bhalla K, George P, Gutti R, Bali P, Tao J, Guo F, Sigua C, Li Y, Cohen P, Atadja P: A combination of histone deacetylase inhibitor LBH-589 and the Hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant Flt-3 tyrosine kinase. Proc Am Soc Clin Oncol (2004) 23:Abs 6541.
109. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S: Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res (2003) 63(23):8420-8427.
110. Kim MS, Blake M, Bask JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 63(21):7291-7300.
111. Biade S, Stobbe CC, Boyd JT, Chapman JD: Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol (2001) 77(10):1033-1042.
112. Camphausen K, Burgan W, Cerra M, Oswald KA, Trepell JB, Lee MJ, Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res (2004) 64(1):316-321.
113. Camphausen K, Scott T, Sproull M, Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res (2004) 10(18 Pt 1):6066-6071.
114. Kim JH, Shin JH, Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys (2004) 59(4):1174-1180.
115. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K: Histone deacetylase inhibitors FK-228, N-(2-aminophenyl)-4-N (pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxy-cinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer (2004) 110(2):301-308.
116. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM: Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery (2001) 130(2):265-272.
117. Inoue H, Shiraki K, Ohmod S, Sakai T, Deguchi M, Yamanaka T, Okano H, Nakano T: Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med (2002) 9 5):521-525.
118. Rosato RR, Almenara JA, Dai Y, Grant S: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther (2003) 2 12):1273-1284.
119. Chinnaiyan P, Varambally S, Tomlins SA, Huang S, Chinnaiyan AM, Harari PM: Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Proc Am Soc Clin Oncol (2004) 23:Abs 3029.
120. Piekarz R, Frye R, Turner BM, Wright J, Leonard J, Allen S, Bates S: Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Proc Am Soc Clin Oncol (2004) 23 Abs 3028.
121. Keer H, Raid T, Sreedharan S: Pivanex activity in refractory nonsmall cell lung cancer, a phase II study. Proc Am Soc Clin Oncol (2002) 21:Abs 1253.
122. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M et al: Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report. J Clin Oncol (1999) 17(3):984-990.
123. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 54(7):1690-1694.
124. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 7 8):2292-2300.
125. Gilbert J, Baker SD, Donehower RC, Herman JG, DeMarzo A, Carducci M: Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase I study of the MT inhibitor, 5-azacytidine (5AC), and the histone deacetylase inhibitor, phenylbutyrate (PB), in refractory solid tumors. Proc Am Soc Clin Oncol (2001) 20(87a):Abs 343.
126. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt: A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res (2002) 8(7):2142-2148.
127. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Kiang M, Schwartz L, Richardson S, Rosa E, Drobnjak M et al Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 9(10 Pt 1):3578-3588.
128. Kristeleit RS, Tandy D, Atadja P, Patnaik A, Scott J, DeBono JS, Judson I, Kaye SB, Workman P, Aherne W: Effects of the histone deacetylase inhibitor (HDACI) LAQ-824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial. Proc Am Soc Clin Oncol (2004) 23:Abs 3023.
129. Atmaca A, Maurer A, Heinzel T, Gottlicher M, Neumann A, Al-Batran SE, Martin E, Bartsch I, Knuth A, Jaeger E: A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol (2004) 23:Abs 3169.